Using cancer drivers to trigger cell death in lymphoma
Official title: HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL
Funded at Stanford University · NIH-10982470 · Data updated 2026-11-12
This study is exploring a new way to help people with Diffuse Large B-Cell Lymphoma by using special molecules that can help cancer cells turn on their own self-destruct buttons, making existing treatments work better and offering a fresh option for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | December 22, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $614,155 |
| NIH project number | 5R01CA276167-03 |
| Project ID | NIH-10982470 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Diffuse Large B-Cell Lymphoma who have not responded adequately to standard therapies.
✕Less likely to help
Patients with other types of lymphoma or those who have already achieved remission may not benefit from this research.
What this research studies
This research investigates a novel approach to treat Diffuse Large B-Cell Lymphoma (DLBCL) by utilizing specially designed molecules that can manipulate cancer cell behavior. The study focuses on rewiring the cancer cell's internal mechanisms to activate genes that promote cell death, effectively causing the cancer cells to self-destruct. By targeting specific proteins that are overactive in DLBCL, the researchers aim to enhance the effectiveness of existing treatments and provide a new therapeutic option for patients. The methodology involves creating bifunctional molecules that can bind to cancer drivers and proapoptotic gene promoters, leading to a significant reduction in cancer cell survival.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with DLBCL, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promise in using similar approaches to target cancer cell mechanisms, indicating potential for success in this novel application.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Crabtree, Gerald R. — Stanford University
- Study coordinator: Crabtree, Gerald R.
Related research
Other NIH-funded projects on the same topics.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
Enhancing CART-T therapy for B-cell lymphoma with longer-lasting IL-7/IL-15/IL-21 support
This grant tests a new treatment approach that combines CAR-T cells for large B-cell lymphoma with a long-acting growth factor cocktail to help the CAR-T cells expand and persist.
-
How Epstein-Barr virus contributes to aggressive B‑cell lymphoma (DLBCL)
This work looks at how Epstein‑Barr virus affects certain types of diffuse large B‑cell lymphoma (DLBCL) to find new treatment targets for people with DLBCL, including those living with HIV.
-
Using lymphoma's own faulty proteins to trigger self‑destruction in diffuse large B‑cell lymphoma
New small molecules aim to bring lymphoma's abnormal proteins to the right DNA switches so diffuse large B‑cell lymphoma cells turn on self‑destruct genes.
-
Analyzing genetic mutations in cancer to improve treatment
This study is looking at the genetic changes that cause cancer to help doctors find better, personalized treatments for cancer patients like you.
-
Targeting MALT1 in African American adults with diffuse large B‑cell lymphoma
This project is developing MALT1‑blocking drugs to help African American adults with aggressive or treatment‑resistant diffuse large B‑cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.